Galecto Gains Momentum with New Drug Class and Strong Funding
Guggenheim initiates coverage on Galecto with a Buy rating and $32 target, citing strong potential for its newly acquired drug DMR-001 and solid funding through 2029.
/ 3 items
#INCY↓
Prelude Therapeutics Refocuses Strategy to Advance Key Cancer Programs
Prelude Therapeutics streamlines its oncology pipeline — prioritizing JAK2V617F and KAT6A programs, pausing SMARCA2, and securing major funding through an Incyte partnership.
Incyte’s INCB0989 Data Shows Early Promise in Myelofibrosis, Analysts Turn Positive
Incyte’s early INCB0989 myelofibrosis data at ASH 2025 looks encouraging, prompting analyst upgrades and higher price targets from Mizuho, Wells Fargo, and Guggenheim.